CG
CERE

Carmignac Gestion’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Carmignac Gestion’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-142,015
Closed -$5.81M – 186
2024
Q2 		$5.81M Hold
142,015
– – 0.1% 73
2024
Q1 		$6M Buy
142,015
+97,834
+221% +$4.11M 0.09% 69
2023
Q4 		$1.87M Buy
+44,181
New +$1.27M 0.03% 110

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Carmignac Gestion's CERE Position: Q3 2024 in Review

Carmignac Gestion sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 142,015 shares — an estimated $5.81M sold.

Carmignac Gestion first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $6M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Carmignac Gestion reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Carmignac Gestion sold 142,015 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $5.81M.
  • Carmignac Gestion first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Carmignac Gestion's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $6M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Carmignac Gestion's 13F filing for Q3 2024, filed 13 Nov 2024.